Sero-prevalence of anti-SARS-CoV-2 antibodies among communities between July and August 2022 in Bangui, Central African Republic
Background. Large-scale population-based seroprevalence studies of SARS-CoV-2 are essential to characterize the cumulative incidence of SARS-CoV-2 infection and to extrapolate the prevalence of presumptive immunity at the population level. Objective. The objective of our survey was to estimate the...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2023-06-01
|
| Series: | Journal of Public Health in Africa |
| Subjects: | |
| Online Access: | https://www.publichealthinafrica.org/jphia/article/view/2315 |
| _version_ | 1797810244689068032 |
|---|---|
| author | Alexandre Manirakiza Christian Malaka Jean de Dieu Longo Brice Martial Yambiyo Saint-Calver Henri Diemer Joella Namseneï Cathy Sandra Gomelle Coti-Reckoundji Modeste Bouhouda Marie Roseline Darnycka Belizaire Jean Baptiste Roungou Narcisse Patrice Komas Gérard Grésenguet Guy Vernet Marie-Astrid Vernet Emmanuel Nakoune |
| author_facet | Alexandre Manirakiza Christian Malaka Jean de Dieu Longo Brice Martial Yambiyo Saint-Calver Henri Diemer Joella Namseneï Cathy Sandra Gomelle Coti-Reckoundji Modeste Bouhouda Marie Roseline Darnycka Belizaire Jean Baptiste Roungou Narcisse Patrice Komas Gérard Grésenguet Guy Vernet Marie-Astrid Vernet Emmanuel Nakoune |
| author_sort | Alexandre Manirakiza |
| collection | DOAJ |
| description |
Background. Large-scale population-based seroprevalence studies of SARS-CoV-2 are essential to characterize the cumulative incidence of SARS-CoV-2 infection and to extrapolate the prevalence of presumptive immunity at the population level. Objective. The objective of our survey was to estimate the cumulative population immunity for COVID-19 and to identify individual characteristics associated with positive serostatus. Materials and Methods. This was a clustered cross-sectional study conducted from July 12 to August 20, 2021, in households in the city of Bangui, the capital of the Central African Republic. Information regarding demographic characteristics (age, gender, and place of residence), and comorbidities (chronic diseases) was collected. A venous blood sample was obtained from each participant to determine the level of total anti-SARS-CoV-2 antibodies using a WANTAI SARS-CoV-2 Ab ELISA kit. Results. All up, 799 participants were surveyed. The average age was 27 years, and 45.8% of the respondents were male (sex ratio: 0.8). The overall proportion of respondents with positive serostatus was 74.1%. Participants over 20 years of age were twice as likely to have positive serostatus, with an OR of 2.2 (95% CI: [1.6, 3.1]). Interpretation. The results of this survey revealed a high cumulative level of immunity in Bangui, thus indicating a significant degree of spread of SARS-CoV-2 in the population. The public health implications of this immunity to SARS-CoV-2 such as the post-vaccination total antibody kinetics remain to be determined.
|
| first_indexed | 2024-03-13T07:05:13Z |
| format | Article |
| id | doaj.art-3ccc14f545b049fabdf35d8d49ae9d12 |
| institution | Directory Open Access Journal |
| issn | 2038-9922 2038-9930 |
| language | English |
| last_indexed | 2024-03-13T07:05:13Z |
| publishDate | 2023-06-01 |
| publisher | PAGEPress Publications |
| record_format | Article |
| series | Journal of Public Health in Africa |
| spelling | doaj.art-3ccc14f545b049fabdf35d8d49ae9d122023-06-06T10:32:24ZengPAGEPress PublicationsJournal of Public Health in Africa2038-99222038-99302023-06-0110.4081/jphia.2023.2315Sero-prevalence of anti-SARS-CoV-2 antibodies among communities between July and August 2022 in Bangui, Central African RepublicAlexandre Manirakiza0Christian Malaka 1Jean de Dieu Longo2Brice Martial Yambiyo 3Saint-Calver Henri Diemer 4Joella Namseneï 5Cathy Sandra Gomelle Coti-Reckoundji6Modeste Bouhouda7Marie Roseline Darnycka Belizaire8Jean Baptiste Roungou9Narcisse Patrice Komas 10Gérard Grésenguet11Guy Vernet12Marie-Astrid Vernet13Emmanuel Nakoune14Institut Pasteur of Bangui, Pasteur International Network, Bangui; Faculté des Sciences de la Santé, Université of Bangui, BanguiInstitut Pasteur of Bangui, Pasteur International Network, BanguiFaculté des Sciences de la Santé, Université of Bangui, Bangui; Ministère de la Santé et de la Population, BanguiInstitut Pasteur of Bangui, Pasteur International Network, BanguiFaculté des Sciences de la Santé, Université of Bangui, BanguiInstitut Pasteur of Bangui, Pasteur International Network, BanguiInstitut Pasteur of Bangui, Pasteur International Network, BanguiInstitut Pasteur of Bangui, Pasteur International Network, BanguiWorld Health Organization, Country Office, BanguiMinistère de la Santé et de la Population, BanguiInstitut Pasteur of Bangui, Pasteur International Network, Bangui; Faculté des Sciences de la Santé, Université of Bangui, BanguiFaculté des Sciences de la Santé, Université of Bangui, BanguiInstitut Pasteur of Bangui, Pasteur International Network, BanguiInstitut Pasteur of Bangui, Pasteur International Network, BanguiInstitut Pasteur of Bangui, Pasteur International Network, Bangui; Faculté des Sciences de la Santé, Université of Bangui, Bangui Background. Large-scale population-based seroprevalence studies of SARS-CoV-2 are essential to characterize the cumulative incidence of SARS-CoV-2 infection and to extrapolate the prevalence of presumptive immunity at the population level. Objective. The objective of our survey was to estimate the cumulative population immunity for COVID-19 and to identify individual characteristics associated with positive serostatus. Materials and Methods. This was a clustered cross-sectional study conducted from July 12 to August 20, 2021, in households in the city of Bangui, the capital of the Central African Republic. Information regarding demographic characteristics (age, gender, and place of residence), and comorbidities (chronic diseases) was collected. A venous blood sample was obtained from each participant to determine the level of total anti-SARS-CoV-2 antibodies using a WANTAI SARS-CoV-2 Ab ELISA kit. Results. All up, 799 participants were surveyed. The average age was 27 years, and 45.8% of the respondents were male (sex ratio: 0.8). The overall proportion of respondents with positive serostatus was 74.1%. Participants over 20 years of age were twice as likely to have positive serostatus, with an OR of 2.2 (95% CI: [1.6, 3.1]). Interpretation. The results of this survey revealed a high cumulative level of immunity in Bangui, thus indicating a significant degree of spread of SARS-CoV-2 in the population. The public health implications of this immunity to SARS-CoV-2 such as the post-vaccination total antibody kinetics remain to be determined. https://www.publichealthinafrica.org/jphia/article/view/2315SARS-CoV-2cumulative immunityBanguiCentral African Republic |
| spellingShingle | Alexandre Manirakiza Christian Malaka Jean de Dieu Longo Brice Martial Yambiyo Saint-Calver Henri Diemer Joella Namseneï Cathy Sandra Gomelle Coti-Reckoundji Modeste Bouhouda Marie Roseline Darnycka Belizaire Jean Baptiste Roungou Narcisse Patrice Komas Gérard Grésenguet Guy Vernet Marie-Astrid Vernet Emmanuel Nakoune Sero-prevalence of anti-SARS-CoV-2 antibodies among communities between July and August 2022 in Bangui, Central African Republic Journal of Public Health in Africa SARS-CoV-2 cumulative immunity Bangui Central African Republic |
| title | Sero-prevalence of anti-SARS-CoV-2 antibodies among communities between July and August 2022 in Bangui, Central African Republic |
| title_full | Sero-prevalence of anti-SARS-CoV-2 antibodies among communities between July and August 2022 in Bangui, Central African Republic |
| title_fullStr | Sero-prevalence of anti-SARS-CoV-2 antibodies among communities between July and August 2022 in Bangui, Central African Republic |
| title_full_unstemmed | Sero-prevalence of anti-SARS-CoV-2 antibodies among communities between July and August 2022 in Bangui, Central African Republic |
| title_short | Sero-prevalence of anti-SARS-CoV-2 antibodies among communities between July and August 2022 in Bangui, Central African Republic |
| title_sort | sero prevalence of anti sars cov 2 antibodies among communities between july and august 2022 in bangui central african republic |
| topic | SARS-CoV-2 cumulative immunity Bangui Central African Republic |
| url | https://www.publichealthinafrica.org/jphia/article/view/2315 |
| work_keys_str_mv | AT alexandremanirakiza seroprevalenceofantisarscov2antibodiesamongcommunitiesbetweenjulyandaugust2022inbanguicentralafricanrepublic AT christianmalaka seroprevalenceofantisarscov2antibodiesamongcommunitiesbetweenjulyandaugust2022inbanguicentralafricanrepublic AT jeandedieulongo seroprevalenceofantisarscov2antibodiesamongcommunitiesbetweenjulyandaugust2022inbanguicentralafricanrepublic AT bricemartialyambiyo seroprevalenceofantisarscov2antibodiesamongcommunitiesbetweenjulyandaugust2022inbanguicentralafricanrepublic AT saintcalverhenridiemer seroprevalenceofantisarscov2antibodiesamongcommunitiesbetweenjulyandaugust2022inbanguicentralafricanrepublic AT joellanamsenei seroprevalenceofantisarscov2antibodiesamongcommunitiesbetweenjulyandaugust2022inbanguicentralafricanrepublic AT cathysandragomellecotireckoundji seroprevalenceofantisarscov2antibodiesamongcommunitiesbetweenjulyandaugust2022inbanguicentralafricanrepublic AT modestebouhouda seroprevalenceofantisarscov2antibodiesamongcommunitiesbetweenjulyandaugust2022inbanguicentralafricanrepublic AT marieroselinedarnyckabelizaire seroprevalenceofantisarscov2antibodiesamongcommunitiesbetweenjulyandaugust2022inbanguicentralafricanrepublic AT jeanbaptisteroungou seroprevalenceofantisarscov2antibodiesamongcommunitiesbetweenjulyandaugust2022inbanguicentralafricanrepublic AT narcissepatricekomas seroprevalenceofantisarscov2antibodiesamongcommunitiesbetweenjulyandaugust2022inbanguicentralafricanrepublic AT gerardgresenguet seroprevalenceofantisarscov2antibodiesamongcommunitiesbetweenjulyandaugust2022inbanguicentralafricanrepublic AT guyvernet seroprevalenceofantisarscov2antibodiesamongcommunitiesbetweenjulyandaugust2022inbanguicentralafricanrepublic AT marieastridvernet seroprevalenceofantisarscov2antibodiesamongcommunitiesbetweenjulyandaugust2022inbanguicentralafricanrepublic AT emmanuelnakoune seroprevalenceofantisarscov2antibodiesamongcommunitiesbetweenjulyandaugust2022inbanguicentralafricanrepublic |